NCT01226277View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions

Solid Cancers

Interventions

DRUG

GDC-0917

Oral repeating dose

Trial Locations (2)

37203

Nashville

98229

San Antonio

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY